Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Raw Materials: 2022-2024

Historic Raw Materials for Arcutis Biotherapeutics (ARQT) over the last 3 years, with Dec 2024 value amounting to $4.3 million.

  • Arcutis Biotherapeutics' Raw Materials rose 49.62% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 million, marking a year-over-year increase of 49.62%. This contributed to the annual value of $4.3 million for FY2024, which is 56.79% down from last year.
  • Arcutis Biotherapeutics' Raw Materials amounted to $4.3 million in FY2024, which was down 56.79% from $10.0 million recorded in FY2023.
  • In the past 5 years, Arcutis Biotherapeutics' Raw Materials ranged from a high of $10.0 million in FY2023 and a low of $4.3 million during FY2024.
  • For the 3-year period, Arcutis Biotherapeutics' Raw Materials averaged around $6.6 million, with its median value being $5.7 million (2022).
  • As far as peak fluctuations go, Arcutis Biotherapeutics' Raw Materials soared by 75.84% in 2023, and later plummeted by 56.79% in 2024.
  • Over the past 3 years, Arcutis Biotherapeutics' Raw Materials (Yearly) stood at $5.7 million in 2022, then skyrocketed by 75.84% to $10.0 million in 2023, then slumped by 56.79% to $4.3 million in 2024.